ACRO Survey Shows Strong Growth of CRO Industry
Members of the Association of Clinical Research Organizations have more than doubled in size in the past 10 years
Members of the Association of Clinical Research Organizations (ACRO) have more than doubled in size in the past 10 years and now employ more than 100,000 research professionals worldwide with a global payroll of nearly $6 billion. Over the same period, member company revenues have increased 180% (10.8% CAGR) to an estimated $14.2 billion, or approximately two-thirds of contract biopharmaceutical development spending, demonstrating the strong demand for CRO services by pharmaceutical, biotech and medical device companies.
Other key findings from the member survey include:
- Among the most researched indications by CROs are, breast cancer, Alzheimer’s Disease, hepatitis, diabetes, asthma, hypertension, and vaccines
- On average, each ACRO member works with more than 500 research sponsors and approximately 27,000 research sites annually
- ACRO members delivered more than 100 million central laboratory test results and managed more than 1 million square feet of lab space in 13 countries
- The top US states for CRO employment are North Carolina, Pennsylvania, Massachusetts, New Jersey, Texas and California; the top European locations for CRO employment are the United Kingdom, Germany, France and Spain
Throughout the next month, ACRO will be unveiling a series of case studies that highlight CRO innovation, as well as a video series focusing several of these topics.
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
